Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This strategic move comes as the company expands its contract development and manufacturing organization (CDMO) capabilities following the acquisition of Recipharm Israel, which is expected to close in the first quarter of 2026.
Kuratz brings over 30 years of leadership experience in supply chain and operations across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is aimed at enhancing the operational efficiency and scalability of Scinai's CDMO services, which are critical to meeting the growing demand for biologics and small-molecule manufacturing.
The expansion of the CDMO platform through the acquisition of Recipharm Israel adds a second development and manufacturing site in Yavne, complementing Scinai's existing operations in Jerusalem. This combined platform offers a comprehensive range of services, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing. These capabilities position Scinai to serve a broader client base and support the development of complex therapies.
“The addition of Eran Kuratz to our team is a key step in strengthening our CDMO operations as we integrate the new Yavne facility,” said a company spokesperson. “His extensive experience in supply chain management and business processes will be invaluable in optimizing our operations and ensuring we deliver high-quality services to our clients.”
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company's CDMO subsidiary, Scinai Biopharma Services, provides development and manufacturing services to biotechnology and pharmaceutical companies through its facilities in Jerusalem and Yavne, Israel.
The appointment of Kuratz underscores Scinai's commitment to enhancing its CDMO offerings and streamlining operations as it integrates new capabilities. By investing in experienced leadership and expanding its manufacturing footprint, Scinai aims to become a leading partner for companies seeking high-quality contract development and manufacturing services in the biopharmaceutical industry.
For more information about Scinai Immunotherapeutics and its CDMO services, visit the company's newsroom at https://ibn.fm/SCNI.
